Home/Pipeline
Program
PreclinicalPhase 1Phase 2Phase 3FiledApproved
Next milestoneCLV-101orevantinibVRX-1 solid tumorsOncology · Small molecule
Label expansion filing 2027
CLV-114tazulimab-cvraMultiple myelomaOncology · Antibody
Earlier-line data H1 2027
CLV-122berolumab-cvraHER-low breast cancer (first line)Oncology · ADC
Regulatory decision Q2 2027
CLV-131emzaratinibNSCLC adjuvantOncology · Small molecule
Phase 3 readout 2027
CLV-140Small cell lung cancerOncology · Bispecific
Phase 2 data at oncology congress
CLV-147Ovarian cancerOncology · ADC
Dose escalation complete
CLV-158Pancreatic cancer (KRAS)Oncology · Small molecule
IND filing 2027
CLV-205solekizumabPlaque psoriasisImmunology · Antibody
Pediatric study ongoing
CLV-219teravolumabHidradenitis suppurativaImmunology · Antibody
Regulatory decision H2 2027
CLV-211corvatinibCrohn's diseaseImmunology · Small molecule
Phase 3 enrollment complete
CLV-226Atopic dermatitisImmunology · Antibody
Phase 2b readout Q4 2026
CLV-233LupusImmunology · Cell therapy
First patient dosed
CLV-302trelanemabEarly Alzheimer's diseaseNeuroscience · Antibody
Subcutaneous form in Phase 3
CLV-310Parkinson's diseaseNeuroscience · Small molecule
Phase 3 readout 2027
CLV-318Treatment-resistant depressionNeuroscience · Small molecule
Phase 2 data Q1 2027
CLV-325ALSNeuroscience · RNA
Candidate selected
CLV-404calvasiranHyperlipidemiaCardiometabolic · RNA
Outcomes study fully enrolled
CLV-412lorvatideObesityCardiometabolic · Peptide
Phase 3 readout H2 2027
CLV-419Heart failure (HFpEF)Cardiometabolic · Antibody
Phase 2 enrollment ongoing
CLV-427Lp(a) elevationCardiometabolic · RNA
Single ascending dose complete
CLV-501elvoparvecSpinal muscular atrophyRare Disease · Gene therapy
Long-term follow-up
CLV-508Duchenne muscular dystrophyRare Disease · Gene therapy
Pivotal cohort dosing
CLV-515Fabry diseaseRare Disease · RNA
First cohort dosed
CLV-522Rett syndromeRare Disease · Gene therapy
IND-enabling studies
Pipeline as of September 30, 2026. Programs and data are fictional.